| Date | TitleTitle | ||||
|---|---|---|---|---|---|
| 09/02/24 | 11:01:01 | 9 Feb 2024 | Notice of Dispute lodged with Stalicla SA | RNS | |
| 16/01/24 | 15:07:32 | 16 Jan 2024 | Series B Fund Raise by partner, Stalicla SA | RNS | |
| 29/12/23 | 11:29:54 | 29 Dec 2023 | Holding(s) in Company | RNS | |
| 22/12/23 | 07:00:06 | 22 Dec 2023 | Directorate Changes | RNS | |
| 13/11/23 | 07:00:14 | 13 Nov 2023 | Upcoming conferences | RNS | |
| 31/10/23 | 07:00:12 | 31 Oct 2023 | Half-year Report | RNS | |
| 26/10/23 | 07:00:14 | 26 Oct 2023 | Erasmus Medical Center begins glioblastoma studies | RNS | |
| 19/10/23 | 14:26:29 | 19 Oct 2023 | Authored Article Publication | RNS | |
| 05/09/23 | 07:00:06 | 5 Sept 2023 | Directorate Changes | RNS | |
| 15/08/23 | 07:00:03 | 15 Aug 2023 | Final Report from Phase 1b PK/PD study | RNS | |
| 03/08/23 | 12:38:35 | 3 Aug 2023 | Rule 17 Disclosure | RNS | |
| 02/08/23 | 07:00:03 | 2 Aug 2023 | Return of rights to Sulforadex from Juvenescence | RNS | |
| 21/07/23 | 12:02:59 | 21 Jul 2023 | Result of AGM | RNS | |
| 27/06/23 | 07:00:05 | 27 Jun 2023 | SFX-01 radiosensitisation effect confirmed in-vivo | RNS | |
| 20/06/23 | 13:59:34 | 20 Jun 2023 | Notice of AGM & Posting of Annual Report | RNS | |
| 19/06/23 | 07:00:04 | 19 Jun 2023 | Grant Success for Glioblastoma studies | RNS | |
| 07/06/23 | 07:00:03 | 7 Jun 2023 | Final Results | RNS | |
| 26/05/23 | 11:00:01 | 26 May 2023 | Notice of Results | RNS | |
| 22/03/23 | 07:00:05 | 22 Mar 2023 | Preliminary results from Phase 1b study | RNS | |
| 16/03/23 | 14:00:19 | 16 Mar 2023 | Price Monitoring Extension | RNS | |
| 16/03/23 | 11:05:36 | 16 Mar 2023 | Second Price Monitoring Extn | RNS | |
| 16/03/23 | 11:00:25 | 16 Mar 2023 | Price Monitoring Extension | RNS | |
| 16/03/23 | 07:00:07 | 16 Mar 2023 | Further evidence of radiosensitisation by SFX-01 | RNS | |
| 13/03/23 | 07:00:07 | 13 Mar 2023 | No exposure to Silicon Valley Bank | RNS | |
| 25/01/23 | 07:00:04 | 25 Jan 2023 | Clinical trial update | RNS | |
| 14/12/22 | 17:08:04 | 14 Dec 2022 | Grant of Options - Director/PDMR Shareholding | RNS | |
| 08/12/22 | 07:00:03 | 8 Dec 2022 | Half-year Report | RNS | |
| 02/12/22 | 07:00:12 | 2 Dec 2022 | Notice of Half Year Results | RNS | |
| 30/11/22 | 14:06:03 | 30 Nov 2022 | Second Price Monitoring Extn | RNS | |
| 30/11/22 | 14:00:34 | 30 Nov 2022 | Price Monitoring Extension | RNS | |
| 16/11/22 | 07:00:04 | 16 Nov 2022 | Study started of new SFX-01 tablet formulation | RNS | |
| 21/10/22 | 11:05:32 | 21 Oct 2022 | Second Price Monitoring Extn | RNS | |
| 21/10/22 | 11:00:34 | 21 Oct 2022 | Price Monitoring Extension | RNS | |
| 12/10/22 | 16:41:03 | 12 Oct 2022 | Second Price Monitoring Extn | RNS | |
| 12/10/22 | 16:35:33 | 12 Oct 2022 | Price Monitoring Extension | RNS | |
| 12/10/22 | 07:00:03 | 12 Oct 2022 | Clinical trial update | RNS | |
| 10/10/22 | 11:05:49 | 10 Oct 2022 | Second Price Monitoring Extn | RNS | |
| 10/10/22 | 11:00:36 | 10 Oct 2022 | Price Monitoring Extension | RNS | |
| 10/10/22 | 07:00:07 | 10 Oct 2022 | SFX-01 licensing deal for up to $160.5m | RNS | |
| 29/09/22 | 07:00:07 | 29 Sept 2022 | Regulatory approval for healthy volunteer study | RNS | |
| 22/07/22 | 07:00:02 | 22 Jul 2022 | Result of AGM | RNS | |
| 14/07/22 | 12:43:38 | 14 Jul 2022 | Investor Presentation | RNS | |
| 06/07/22 | 12:25:32 | 6 Jul 2022 | Notice of AGM | RNS | |
| 13/06/22 | 07:00:07 | 13 Jun 2022 | Collaboration with University of Michigan | RNS | |
| 08/06/22 | 07:00:10 | 8 Jun 2022 | Full Year Results | RNS | |
| 07/06/22 | 07:00:08 | 7 Jun 2022 | Notice of Results | RNS | |
| 25/05/22 | 07:00:10 | 25 May 2022 | Collaboration with Università Sapienza di Roma | RNS | |
| 29/04/22 | 14:39:40 | 29 Apr 2022 | Holding(s) in Company | RNS | |
| 15/03/22 | 14:05:48 | 15 Mar 2022 | Second Price Monitoring Extn | RNS | |
| 15/03/22 | 14:00:43 | 15 Mar 2022 | Price Monitoring Extension | RNS |
| Date | TitleTitle | ||||
|---|---|---|---|---|---|
| 09/02/24 | 11:01:01 | 9 Feb 2024 | Notice of Dispute lodged with Stalicla SA | RNS | |
| 16/01/24 | 15:07:32 | 16 Jan 2024 | Series B Fund Raise by partner, Stalicla SA | RNS | |
| 29/12/23 | 11:29:54 | 29 Dec 2023 | Holding(s) in Company | RNS | |
| 22/12/23 | 07:00:06 | 22 Dec 2023 | Directorate Changes | RNS | |
| 13/11/23 | 07:00:14 | 13 Nov 2023 | Upcoming conferences | RNS | |
| 31/10/23 | 07:00:12 | 31 Oct 2023 | Half-year Report | RNS | |
| 26/10/23 | 07:00:14 | 26 Oct 2023 | Erasmus Medical Center begins glioblastoma studies | RNS | |
| 19/10/23 | 14:26:29 | 19 Oct 2023 | Authored Article Publication | RNS | |
| 05/09/23 | 07:00:06 | 5 Sept 2023 | Directorate Changes | RNS | |
| 15/08/23 | 07:00:03 | 15 Aug 2023 | Final Report from Phase 1b PK/PD study | RNS | |
| 03/08/23 | 12:38:35 | 3 Aug 2023 | Rule 17 Disclosure | RNS | |
| 02/08/23 | 07:00:03 | 2 Aug 2023 | Return of rights to Sulforadex from Juvenescence | RNS | |
| 21/07/23 | 12:02:59 | 21 Jul 2023 | Result of AGM | RNS | |
| 27/06/23 | 07:00:05 | 27 Jun 2023 | SFX-01 radiosensitisation effect confirmed in-vivo | RNS | |
| 20/06/23 | 13:59:34 | 20 Jun 2023 | Notice of AGM & Posting of Annual Report | RNS | |
| 19/06/23 | 07:00:04 | 19 Jun 2023 | Grant Success for Glioblastoma studies | RNS | |
| 07/06/23 | 07:00:03 | 7 Jun 2023 | Final Results | RNS | |
| 26/05/23 | 11:00:01 | 26 May 2023 | Notice of Results | RNS | |
| 22/03/23 | 07:00:05 | 22 Mar 2023 | Preliminary results from Phase 1b study | RNS | |
| 16/03/23 | 14:00:19 | 16 Mar 2023 | Price Monitoring Extension | RNS | |
| 16/03/23 | 11:05:36 | 16 Mar 2023 | Second Price Monitoring Extn | RNS | |
| 16/03/23 | 11:00:25 | 16 Mar 2023 | Price Monitoring Extension | RNS | |
| 16/03/23 | 07:00:07 | 16 Mar 2023 | Further evidence of radiosensitisation by SFX-01 | RNS | |
| 13/03/23 | 07:00:07 | 13 Mar 2023 | No exposure to Silicon Valley Bank | RNS | |
| 25/01/23 | 07:00:04 | 25 Jan 2023 | Clinical trial update | RNS | |
| 14/12/22 | 17:08:04 | 14 Dec 2022 | Grant of Options - Director/PDMR Shareholding | RNS | |
| 08/12/22 | 07:00:03 | 8 Dec 2022 | Half-year Report | RNS | |
| 02/12/22 | 07:00:12 | 2 Dec 2022 | Notice of Half Year Results | RNS | |
| 30/11/22 | 14:06:03 | 30 Nov 2022 | Second Price Monitoring Extn | RNS | |
| 30/11/22 | 14:00:34 | 30 Nov 2022 | Price Monitoring Extension | RNS | |
| 16/11/22 | 07:00:04 | 16 Nov 2022 | Study started of new SFX-01 tablet formulation | RNS | |
| 21/10/22 | 11:05:32 | 21 Oct 2022 | Second Price Monitoring Extn | RNS | |
| 21/10/22 | 11:00:34 | 21 Oct 2022 | Price Monitoring Extension | RNS | |
| 12/10/22 | 16:41:03 | 12 Oct 2022 | Second Price Monitoring Extn | RNS | |
| 12/10/22 | 16:35:33 | 12 Oct 2022 | Price Monitoring Extension | RNS | |
| 12/10/22 | 07:00:03 | 12 Oct 2022 | Clinical trial update | RNS | |
| 10/10/22 | 11:05:49 | 10 Oct 2022 | Second Price Monitoring Extn | RNS | |
| 10/10/22 | 11:00:36 | 10 Oct 2022 | Price Monitoring Extension | RNS | |
| 10/10/22 | 07:00:07 | 10 Oct 2022 | SFX-01 licensing deal for up to $160.5m | RNS | |
| 29/09/22 | 07:00:07 | 29 Sept 2022 | Regulatory approval for healthy volunteer study | RNS | |
| 22/07/22 | 07:00:02 | 22 Jul 2022 | Result of AGM | RNS | |
| 14/07/22 | 12:43:38 | 14 Jul 2022 | Investor Presentation | RNS | |
| 06/07/22 | 12:25:32 | 6 Jul 2022 | Notice of AGM | RNS | |
| 13/06/22 | 07:00:07 | 13 Jun 2022 | Collaboration with University of Michigan | RNS | |
| 08/06/22 | 07:00:10 | 8 Jun 2022 | Full Year Results | RNS | |
| 07/06/22 | 07:00:08 | 7 Jun 2022 | Notice of Results | RNS | |
| 25/05/22 | 07:00:10 | 25 May 2022 | Collaboration with Università Sapienza di Roma | RNS | |
| 29/04/22 | 14:39:40 | 29 Apr 2022 | Holding(s) in Company | RNS | |
| 15/03/22 | 14:05:48 | 15 Mar 2022 | Second Price Monitoring Extn | RNS | |
| 15/03/22 | 14:00:43 | 15 Mar 2022 | Price Monitoring Extension | RNS |